Spyre Therapeutics (SYRE) Gains from Investment Securities (2015 - 2024)

Spyre Therapeutics posted quarterly Gains from Investment Securities of -$200000.0 for Q2 2024, down 100.32% year-on-year from $63.4 million in Q3 2023, and up 78.0% on a QoQ basis from -$909000.0 in Q3 2023.

Spyre Therapeutics (SYRE) has 10 years of Gains from Investment Securities data on file, last reported at -$200000.0 in Q2 2024.

  • For the quarter ending Q2 2024, Gains from Investment Securities fell 100.32% year-over-year to -$200000.0; the trailing twelve-month figure through Dec 2024 stood at -$200000.0 (down 29.87% YoY), and the FY2023 full-year result was -$915000.0, down 109.04% from the prior year.
  • Gains from Investment Securities for Q2 2024 stood at -$200000.0, up from -$909000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $63.4 million in Q2 2023 and bottomed at -$909000.0 in Q3 2023.
  • The 5-year median for Gains from Investment Securities is $366600.0 (2021), against an average of $4.8 million.
  • The widest annual swing landed in 2022, when Gains from Investment Securities soared 42760.0%; it then slumped 123.66% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at -$14000.0 in 2020, then jumped by 2507.14% to $337000.0 in 2021, then rose by 24.04% to $418000.0 in 2022, then sank by 317.46% to -$909000.0 in 2023, then jumped by 78.0% to -$200000.0 in 2024.
  • The last three Gains from Investment Securities figures came in at -$200000.0 (Q2 2024), -$909000.0 (Q3 2023), and $63.4 million (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Spyre Therapeutics 5.55 Bn 5.55 Bn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2024 -200,000.00
Jun 30, 2024 -200,000.00
Sep 30, 2023 -909,000.00
Sep 30, 2023 -909,000.00
Jun 30, 2023 63.42 Mn
Jun 30, 2023 63.42 Mn
Mar 31, 2023 4.44 Mn
Mar 31, 2023 4.44 Mn
Dec 31, 2022 418,000.00
Dec 31, 2022 418,000.00
Sep 30, 2022 3.84 Mn
Sep 30, 2022 3.84 Mn
Jun 30, 2022 429,000.00
Jun 30, 2022 429,000.00
Mar 31, 2022 2.14 Mn
Mar 31, 2022 2.14 Mn
Dec 31, 2021 337,000.00
Dec 31, 2021 337,000.00
Sep 30, 2021 396,200.00
Sep 30, 2021 396,200.00
Jun 30, 2021 2.16 Mn
Jun 30, 2021 2.16 Mn
Mar 31, 2021 5,000.00
Mar 31, 2021 5,000.00
Dec 31, 2020 -14,000.00
Dec 31, 2020 -14,000.00
Sep 30, 2020 228,200.00
Sep 30, 2020 228,200.00
Jun 30, 2020 239,400.00
Jun 30, 2020 239,400.00
Mar 31, 2020 7,000.00
Mar 31, 2020 7,000.00
Dec 31, 2019 -18,000.00
Dec 31, 2019 -18,000.00
Sep 30, 2019 44,000.00
Sep 30, 2019 44,000.00
Jun 30, 2019 1.20 Mn
Jun 30, 2019 1.20 Mn
Mar 31, 2019 6,000.00
Mar 31, 2019 6,000.00
Dec 31, 2018 -30,000.00
Dec 31, 2018 -30,000.00
Sep 30, 2018 1.29 Mn
Sep 30, 2018 1.29 Mn
Jun 30, 2018 203,600.00
Jun 30, 2018 203,600.00
Mar 31, 2018 829,500.00
Mar 31, 2018 829,500.00
Dec 31, 2017 -15,000.00
Dec 31, 2017 -15,000.00
Sep 30, 2017 735,600.00
Sep 30, 2017 735,600.00
Jun 30, 2017 244,100.00
Jun 30, 2017 244,100.00
Mar 31, 2017 772,800.00
Mar 31, 2017 772,800.00
Dec 31, 2016 -6,000.00
Dec 31, 2016 -6,000.00
Sep 30, 2016 11,562.00
Sep 30, 2016 11,562.00
Jun 30, 2016 720,217.00
Jun 30, 2016 720,217.00
Mar 31, 2016 84,417.00
Mar 31, 2016 84,417.00
Dec 31, 2015 21,000.00
Dec 31, 2015 21,000.00
Sep 30, 2015 644,505.00
Sep 30, 2015 644,505.00
Jun 30, 2015 544,059.00
Jun 30, 2015 544,059.00
Mar 31, 2015 -2,000.00
Mar 31, 2015 -2,000.00